AstraZeneca PLC has agreed to pay US$9.2 million (US$12 million) to settle allegations that it marketed and promoted the blockbuster heartburn drug, esomeprazole, without disclosing financial or commercial information. AstraZeneca will pay a combined $9.2 million, a sum disclosed in a settlement of claims made in a class action suit filed in state court against the company. The US$9.2 million is part of AstraZeneca's $9.25 billion settlement with the class action plaintiffs who claimed that the company promoted the drug without disclosing that it had paid its costs for marketing and sales.
The US$9.2 million represents an upfront payment of $12 million and represents AstraZeneca's third-quarter financial results, which are reported in the U. S. financial press. The payment was made on September 15, 2011, and will remain on future earnings-based forecasts. The payment is part of a group of paymentsONDON - September 2015 - The British company AstraZeneca PLC has agreed to pay US$9.2 million (US$12 million) to settle allegations that it marketed and promoted the blockbuster heartburn drug, esomeprazole, without disclosing financial or commercial information.AstraZeneca's (AZN) US$9.2 million is part of a $9.25 billion settlement with the class action plaintiffs who claimed that the company promoted the drug without disclosing that it had paid its costs for marketing and sales
The UK-based company AstraZeneca PLC is also in the process of settling a class action lawsuit filed by three British companies against AstraZeneca PLC, alleging that it marketed and promoted the blockbuster drug Nexium and other related products as part of a larger health-related litigation in the United Kingdom. AstraZeneca has agreed to pay an undisclosed amount to settle a suit filed in the United Kingdom on behalf of patients suffering from stomach ulcers. The settlement is contingent on a final outcome in the UK litigation which will include a verdict in AstraZeneca's favour and a resolution of AstraZeneca's remaining claims.
This settlement follows AstraZeneca's announcement of its plans to pay $3.3 billion (US$4.8 billion) to settle class action lawsuits filed by British and German plaintiffs in the United Kingdom. The settlements were reached by a group of companies including Apotex Pharmaceuticals PLC (Apotex) and Eli Lilly & Co (L& Co) which settled with the plaintiffs in Europe and Japan and in Germany.
1
AstraZeneca has agreed to pay US$9.2 million (US$12 million) to settle allegations that it marketed and promoted the blockbuster heartburn drug, esomeprazole, without disclosing financial or commercial information. AstraZeneca will pay a combined $9.2 million, a sum announced on September 15, 2011, and will remain on future earnings-based forecasts.
AstraZeneca will pay a combined $9.25 billion, a payment of US$12.5 million (US$12.5 million) to settle claims made in a class action lawsuit against the company, which was brought by three British companies in the United Kingdom. The settlement is contingent on a final outcome in the UK litigation which will include a verdict in AstraZeneca's favor and a resolution of AstraZeneca's remaining claims.
The settlement follows AstraZeneca's announcement of its plan to pay $3.3 billion (US$4.8 billion) to settle class action lawsuits filed by British and German class action suits against the company, which was brought by three British companies in the United Kingdom and in Germany.
AstraZeneca has agreed to pay US$9.
The Food and Drug Administration (FDA) is advising consumers not to purchase or use NEXIUM® (esomeprazole magnesium) capsules, the world's most popular prescription medication, which is used to treat frequent heartburn and gastroesophageal reflux disease (GERD), including esomeprazole.
FDA laboratory analysis confirmed that the capsules contain esomeprazole, which is also known as omeprazole. NEXIUM® is an over-the-counter (OTC) product that is sold under the brand name Nexium. The FDA has approved NEXIUM® capsules to treat frequent heartburn and to protect the stomach from acid, which may lead to the development of gastric ulcers.
NEXIUM® is not approved for the prevention of heartburn in adults or children under the age of 18. It is not approved for the prevention of GERD, other ulcers, or for the treatment of Zollinger-Ellison syndrome, a rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus. NEXIUM® is not approved for the treatment of Zollinger-Ellison syndrome, another rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus.
NEXIUM® is not approved to treat the symptoms of Zollinger-Ellison syndrome, a rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus. It is not approved for the treatment of Zollinger-Ellison syndrome, another rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus.
The Food and Drug Administration (FDA) has advised consumers not to purchase or use NEXIUM® capsules, the world's best-selling prescription medication, which is used to treat frequent heartburn and gastroesophageal reflux disease (GERD) including esomeprazole, a proton pump inhibitor. The FDA has also cautioned consumers to visit their doctor if they experience a persistent burning pain in their chest after taking NEXIUM®.
The Food and Drug Administration (FDA) has advised consumers to visit their doctor if they experience persistent burning pain after taking NEXIUM®. The medication is not approved for the prevention of Zollinger-Ellison syndrome, a rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus. The drug is not approved for the treatment of Zollinger-Ellison syndrome, another rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus.
The FDA has advised consumers to visit their doctor if they experience persistent burning pain in their chest after taking NEXIUM®. The medication is not approved for the prevention of Zollinger-Ellison syndrome, another rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus.
The FDA has recommended that consumers avoid using NEXIUM® to treat other conditions, including those that are related to acid reflux or heartburn, and that the drug be considered an OTC product only if it is being used to treat heartburn or gastroesophageal reflux disease (GERD). The product should not be used in the treatment of Zollinger-Ellison syndrome, another rare genetic condition in which the immune system mistakenly attacks the lining of the esophagus.
One of the most frequently prescribed medications for gastroesophageal reflux disease (GERD) is Nexium. The FDA-approved brand name for this medication is Nexium. It is available in generic form in both brand and generic forms. Generic versions are also available in the U. S. as well. Generic versions of Nexium are the same active ingredient as the brand version, which is intended to be as safe and effective as possible for consumers.
Nexium is used to treat symptoms of heartburn, acid reflux, and GERD. It is also used to prevent the development of stomach ulcers and to lower the risk of stomach ulcers in certain individuals. Nexium works by relaxing the walls of the stomach and increasing the amount of acid produced.
Nexium can be taken with or without food. The recommended dosage is usually 50 to 100 mg per day. However, taking it at the same time each day may help prevent stomach irritation.
Nexium may cause side effects such as:
In some cases, more serious side effects may be possible. Call your doctor right away if you have any of the following symptoms:
Nexium is known as a prescription medication. It can be taken once or twice per day for different conditions. It is typically taken on a daily basis and lasts for up to 14 days. This medication can be used to help treat acid reflux, GERD, and other symptoms of GERD.
Like any medication, Nexium can cause side effects. Common side effects may include:
Contact your doctor immediately if any of the following side effects occur.
Nexium should be stored at room temperature, away from direct sunlight and moisture. Keep it out of reach of children and pets. Keep the medicine out of reach of children and pets.
Before starting any new medication, it is important to tell your doctor if you have heart disease, a history of stomach problems, liver or kidney disease, a history of certain types of blood disorders, or if you are pregnant or breastfeeding. The medication should only be used to treat GERD or for other health problems.
Tell your doctor if you are taking, or have recently taken, any prescription medication. It is also important to tell your doctor about any herbal or dietary supplements you are taking. You may also be prescribed a prescription medicine if you are not sure about any of the other symptoms of heartburn, acid reflux, and GERD. Call your doctor or pharmacist for more information.
Like all medications, Nexium can cause side effects.
Alternate Name:Pharmapure RX Esomep-EZS
Description:Nexium treats gastroesophageal reflux disease (GERD), esophagitis, and stomach ulcers. The generic version of Nexium is esomeprazole magnesium. For a supply of 30 oral tablets of Nexium Delayed-Release Capsules 40 mg is approximately $287. Take advantage of our LowerMyRx discount to receive a typical Nexium discount of up to 80% off of the retail price at participating pharmacies near you.
Dosage Form:Capsule Delayed Release
Administration Route:By mouth
Drug Class:Gastric Acid Secretion Inhibitor, Gastrointestinal Agent
Generic Available:Yes
Strength:20 MG
Warnings:Tell your doctor if you are pregnant or breastfeeding, or if you have kidney disease, liver disease, lupus, vitamin B12 deficiency, or osteoporosis. This medicine may cause the following problems: Kidney problems, including acute tubulointerstitial nephritisIncreased risk of broken bones in the hip, wrist, or spine (more likely if used several times per day or longer than 1 year)Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms (DRESS)LupusFundic gland polyps (abnormal growth in the upper part of your stomach) This medicine can cause diarrhea. Call your doctor if the diarrhea becomes severe, does not stop, or is bloody. Do not take any medicine to stop diarrhea until you have talked to your doctor. Diarrhea can occur 2 months or more after you stop taking this medicine. Tell any doctor or dentist who treats you that you are using this medicine. This medicine may affect certain medical test results. Your doctor will do lab tests at regular visits to check on the effects of this medicine. Keep all appointments. Keep all medicine out of the reach of children. Never share your medicine with anyone. Stomach pain, nausea, vomiting, weight loss, bloody or black stools
Food Warnings:Do not use esomeprazole if you are also using medicines that contain rilpivirine., Some medicines can affect how esomeprazole works. Tell your doctor if you are using any of the following: Atazanavir, cilostazol, diazepam, digoxin, erlotinib, ketoconazole, methotrexate, mycophenolate mofetil, nelfinavir, rifampin, saquinavir, St John's wort, tacrolimus, voriconazoleBlood thinner (including clopidogrel or warfarin)Diuretic (water pill)Iron supplements, This medicine can cause diarrhea. Diarrhea can occur 2 months or more after you stop taking this medicine., Tell any doctor or dentist who treats you that you are using this medicine. This medicine may affect certain medical test results., Your doctor will check your progress and the effects of this medicine at regular visits. Keep all appointments., Keep all medicine out of the reach of children.
YouPAPURE RXES| Medication | Product Type | Product Warnings |
|---|---|---|
| Esomeprazole Delayed-Release Capsules | Delayed-release capsules | |
| Nexium | Delayed-release capsules | Nexium Delayed-Release Capsules |
| Oxycodone Misuse | Misuse | Oxycodone Misuse |
| Other Esomeprazole Disintegrating Capsules |
Tell your doctor immediately if you develop a seizure.
The expiry for this product is 04/2026. It was last checked and updated on 03/2025. This is an estimate and expiry may vary at the time of supply.
This product is ainsuit Authority - (CQ) Tier 1 Tier. It is a Product of NEXIUM CLAVULAFIAL 1.2mg and is a Product of NEXIUM CLAVULAFIAL 1.4mg.
HALEY K. BECRIE, PHARMACEUTICAL INDIA: GLYCIN B.
What is glucosin? A well-known, easy to crush, the glucosin glycosin contains both glucose and sodium, a type of cell wall. The glycosaminoglycan consists of an alkyl group of glucose residues, and an hydrolyzed group of sodium residues.
The glucosin group of residues is a basic structural part of the cell wall, the alkyl group of sodium residues is a basic structural part of the cell wall. They are required to cross the cell wall to form the cell wall, and this interferes with the activity of the cell wall, and thus the cell permeability, of the cell.
The sodium residues are a basic structural part of the cell wall.
The hydrolyzed group of sodium residues is a basic structural part of the cell wall.
They are required to cross the cell wall to form the cell wall, and this interferes with the activity of the cell wall, and thereby the cell permeability, of the cell.
Stade de France Pharmacy